Key result
This review summarizes the current evidence regarding the efficacy and safety of direct oral anticoagulants in patients with cirrhosis, highlighting the limited data available for this population.
Why the study?
Patients with cirrhosis are prone to thrombus formation, but medical literature includes limited data on the efficacy and safety of DOACs in this population.
Are DOACs safe and effective for anticoagulation in patients with cirrhosis?
Are DOACs safe and effective for anticoagulation in patients with cirrhosis?
This review summarizes the limited current evidence regarding the efficacy and safety of DOACs in patients with cirrhosis.
The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile.
No takes yet. Share an insight, caveat, or question.
Elhosseiny et al. (2019) conducted a review in Cirrhosis. Direct Oral Anticoagulants (DOACs) was evaluated. This review summarizes the current evidence regarding the efficacy and safety of direct oral anticoagulants in patients with cirrhosis, highlighting the limited data available for this population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: